“ Celemics’ TrueRepertoire™ Solution overcomes the limitations of current antibody discovery methodologies and NGS-based immune repertoire analysis”
The current in vitro screening method for antibody discovery selects clones at random, then proceeds with an assay, leading to a high chance of repeated discovery of the same antibody existing in large quantities as well as a low chance of finding antibodies with various characteristics and binding capacities existing at low frequencies.
In contrast, switching in vitro screening and DNA sequence analysis steps enables confirming the antibody sequences in the library and checking their binding capacities without repeatedly discovering identical antibodies. This has allowed our clients to obtain increased number of clones with confirmed binding capacities in the most cost-effective way compared to conventional methods. With TrueRepertoire™, our clients can discover rare clones that have not been detected previously with drastically reduced time and cost.